Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Location contact
Aaron S. Mansfield, M.D.
PRINCIPAL_INVESTIGATOR
Clinical Trials Referral Office
CONTACT
NCT Number: NCT05530759
This study characterizes deoxyribonucleic acid (DNA) and proteomic (protein) changes in both biopsies and tumors removed during surgery of patients who have been diagnosed with aggressive/metastatic (that has spread to other places in the body) cancer in order to identify possible diagnostic markers and potential drugs for treating aggressive tumor types. Proteomic analyses include looking at the proteome, or all the proteins expressed, or made by DNA at a specific moment in time. Studying samples of blood, buccal (cheek), and tissue in the laboratory from patients undergoing surgical resection or biopsy may help doctors learn more about the changes that occur in the proteome, DNA alterations, and identify molecular biomarkers for which therapeutic drugs may exist. Studying the DNA in tumor tissue and in blood may also help researchers see if the tumor has important differences.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Rochester, Minnesota, 55905, United States
Location status: Recruiting
Aaron S. Mansfield, M.D.
PRINCIPAL_INVESTIGATOR
Clinical Trials Referral Office
CONTACT
PRIMARY OBJECTIVES:
I. To understand the pathogenesis, molecular mechanisms, and disease processes of malignancies.
II. To examine the utility of integrated genomics for discovery of targets or pathways involved in tumor/malignancy progression of patients with malignancies.
III. To observe for any evidence of anti-tumor activity from treatment if selected based on integrated genomics.
IV. To create and offer opportunities for targeted individualized therapy based on the outcome of integrated genomics and micro-cancer modeling.
V. To determine the outcome of patients with malignancies who received targeted individualized therapy.
OUTLINE: This is an ancillary-correlative study.
Patients undergo collection of blood and buccal samples before or after standard of care (SOC) biopsy or tumor resection. Patients undergo collection of tumor tissue at time of SOC biopsy or tumor resection. Patients' medical records are also reviewed. Patients' archived tissue or blood samples may also be collected.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Undergo collection of tissue samples
Other names: Biopsy Sample
Undergo collection of blood and buccal swab samples
Other names: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Undergo collection of archived tissue and blood samples
Other names: Biological Sample Collection, Biospecimen Collected, Biospecimen Collection, Specimen Collection
Review of medical record
Other names: Chart Review
Time frame: Through study completion; up to five years
identify molecular targets for which therapeutic drugs may exist
Time frame: Through study completion; up to five years
identify molecular targets for which therapeutic drugs may exist
Mayo Clinic
Other
Integrated Genomics and Patient-Derived Cancer Models
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06015932
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Rochester, Minnesota, United States
View Trial DetailsNCT03583255
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Houston, Texas, United States
View Trial DetailsNCT05564468
Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm
Seattle, Washington, United States
View Trial DetailsNCT04022239
Hematopoietic and Lymphoid System Neoplasm
Houston, Texas, United States
View Trial Details